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Background
The 2016/17 ongoing influenza epidemic in France is characterized by the predominant circulation of A(H3N2) viruses (>96%) 1 
Objectives
In this context, we estimated early 2016/17 influenza vaccine effectiveness (IVE) in primary care against laboratory-confirmed A(H3N2) infection in France. We reported temporal dynamic of IVE in preventing influenza-like illness (ILI) among target groups for vaccination for the last six influenza epidemics, with particular focus on epidemic seasons marked by the circulation of A(H3N2).
Study design
As previously described 5, 6 , sentinel general practitioners (GPs) of the French Sentinelles network reported through the year ILI cases observed in their practice using the following definition: "sudden onset of fever >39°C (102°F) with respiratory signs and myalgia" 7 . They collected simultaneously nasopharyngeal swabs along with clinical information in a randomized sample of their ILI patients during the influenza surveillance period. Clinical information concerns at least: date of consultation, age, sex, vaccine status for current seasonal influenza trivalent vaccine (all brands), time since vaccination (more or less than 2 weeks), presence of risk factors (chronic illness). Influenza virus typing and influenza A subtyping were conducted using real-time RT-PCR assays by the French National Influenza
Reference Center (CNR, Paris and Lyon) and the laboratory of Virology at the University of Corsica.
All nasopharyngeal specimens collected between 3 rd October 2016 (2016w40) and 5 th February 2017 (2017w05) ( Figure 1 ) were included in the Test-negative design (TND) study 8, 9 . IVE were estimated as 1 -(odds ratio) x 100 obtained using multivariable logistic regression models with influenza virological result as outcome and vaccination status as main effect, while adjusting for age (eight groups), time of onset of symptoms, presence of a chronic disease and sex. Patients recruited outside the virus circulation period as defined by the ECDC protocol were excluded 10 .
IVE in preventing medically attended ILI in target groups was estimated by the screening method 5, 11 for the ongoing epidemic and over the 2010/11 to 2015/16 epidemics (http://www.sentiweb.fr 12 ). Proportions of vaccinated cases were computed among ILI cases reported during the epidemic periods. The proportion of vaccinated subjects among the reference population was obtained from administrative sources 13 . IVE estimates were stratified according to age (<65 years with chronic disease; ≥65 years) 14 .
Patients with missing values for any of the variables included in the analysis were excluded, as well as children under six months who are not given the vaccine. Vaccines were considered as potentially effective if administrated at least 2 weeks prior to the symptoms onset. Patients whose vaccination occurred <2 weeks prior to symptoms onset were considered as not vaccinated.
Results
In A total of 2,088 swabbed patients (1,135 A(H3N2) cases and 953 controls) were eligible for inclusion in the TND study (Table 1 ). Adjusted IVE estimates against A(H3N2) were 48% (95% confidence interval (CI): 22 to 66) among the overall population, 34% (95% CI: -6 to 60) among all target groups and 35% (95% CI -23 to 66) among elderly (aged ≥65 y) ( Table   2 ).
Early 2016/17 IVE in preventing ILI was estimated 54% among all target groups (95% CI: 47 to 60) and 47% among elderly (95% CI: 38 to 55) ( Table 2 ). The dynamic of estimated IVE in preventing ILI for the six last influenza epidemics is reported in Figure 2 .
Discussion
For the overall population consulting in primary care, our early 2016/17 IVE estimates against influenza A(H3N2) in France suggest a moderate protection of 48% (95% CI: 22 to 66).
Among elderly, IVE point estimates against A(H3N2) were slightly lower than the overall estimates, but considering the large CI -due to the small sample size, this difference is not 3, 19 . Second, the limited sample size for target groups did not allow estimating accurate IVE among this population.
Third, IVE estimates through the screening method could be biased by using a non-specific influenza outcome 20 . However, the use of the same standardized database and methodology over the years 5, 21 allowed comparison of IVE levels over the seven influenza epidemics here compared.
Conclusion
We report early 2016/17 IVE estimates of 48% for the 2016/17 influenza A(H3N2) epidemic in France. Even if we were not able to report statistical significant IVE against A(H3N2) among elderly, we described trough the screening method a not significant decrease of IVE 6 among this target group. Efforts should be increased to investigate IVE among at risk populations.
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